Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study

Alimentary Pharmacology & Therapeutics
J Molina-InfanteEuropean Registry on H. pylori management (Hp‐EuReg)

Abstract

Empiric triple therapy for Helicobacter pylori should be abandoned when clarithromycin resistance rate is >15-20%. Optimisation of triple therapy (high-dose acid suppression and 14-day duration) can increase eradication rates by 10%. To compare the efficacy and safety of optimised triple (OPT-TRI) and nonbismuth quadruple concomitant (OPT-CON) therapies. Prospective multicentre study in 16 Spanish centres using triple therapy in clinical practice. In a 3-month two-phase fashion, the first 402 patients received an OPT-TRI therapy [esomeprazole (40 mg b.d.), amoxicillin (1 g b.d) and clarithromycin (500 mg b.d) for 14 days] and the last 375 patients an OPT-CON treatment [OPT-TRI therapy plus metronidazole (500 mg b.d)]. Seven-hundred seventy-seven consecutive patients were included (402 OPT-TRI, 375 OPT-CON). The OPT-CON therapy achieved significantly higher eradication rates in the per-protocol [82.3% (95% CI = 78-86%) vs. 93.8% (91-96%), P < 0.001] and intention-to-treat analysis [81.3% (78-86%) vs. 90.4% (87-93%), P < 0.001]. Adverse events (97% mild/moderate) were significantly more common with OPT-CON therapy (39% vs. 47%, P = 0.016), but full compliance with therapy was similar between groups (94% vs. 92%, P = 0.4). OPT-CON...Continue Reading

References

Jul 5, 2007·The American Journal of Gastroenterology·William D CheyUNKNOWN Practice Parameters Committee of the American College of Gastroenterology
Jan 8, 2009·Journal of Clinical Pharmacy and Therapeutics·J L TongS D Xiao
Oct 1, 2009·Journal of Gastroenterology and Hepatology·K Ming FockUNKNOWN Second Asia-Pacific Conference
Mar 13, 2012·Alimentary Pharmacology & Therapeutics·D Y Graham, L A Fischbach
Mar 30, 2012·Clinical and Experimental Gastroenterology·Javier P Gisbert, Xavier Calvet
Apr 12, 2012·Gut·Peter MalfertheinerUNKNOWN European Helicobacter Study Group
Jul 26, 2012·Alimentary Pharmacology & Therapeutics·A HorvathH Szajewska
Aug 11, 2012·European Journal of Internal Medicine·Angelo ZulloDino Vaira
Apr 23, 2013·Gastroenterología y hepatología·Javier P GisbertJordi Sánchez-Delgado
Apr 30, 2013·Gastroenterología y hepatología·Javier Molina-Infante, Javier P Gisbert
May 10, 2013·Alimentary Pharmacology & Therapeutics·F SierraA Cárdenas
Jun 12, 2013·Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association·David Y GrahamMing-Shiang Wu
Jan 11, 2014·Gastroenterology·Sotirios D GeorgopoulosAndreas Mentis

❮ Previous
Next ❯

Citations

Sep 4, 2015·Expert Opinion on Pharmacotherapy·Sotirios D GeorgopoulosStylianos Karatapanis
Sep 16, 2015·Helicobacter·Anthony O'ConnorSpiros Ladas
Nov 7, 2015·Revista Española De Enfermedades Digestivas : Organo Oficial De La Sociedad Española De Patología Digestiva·Sergio Solorio-LópezClotilde Fuentes Orozco
Mar 5, 2015·Alimentary Pharmacology & Therapeutics·N Vakil
Apr 23, 2016·Gastroenterology·Carlo A FalloneJohn K Marshall
Jun 28, 2016·Gastroenterología y hepatología·Javier P GisbertAdrián G McNicholl
Oct 23, 2016·Lancet·Francis Megraud, Javier P Gisbert
Oct 23, 2016·Lancet·Jyh-Ming LiouUNKNOWN Taiwan Gastrointestinal Disease and Helicobacter Consortium
Jan 28, 2020·Journal of Gastroenterology and Hepatology·Jyh-Ming LiouMing-Shiang Wu
Mar 4, 2020·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·Paúl A CárdenasManuel E Baldeón
Mar 5, 2015·Alimentary Pharmacology & Therapeutics·J Molina-InfanteJ P Gisbert
Sep 29, 2019·World Journal of Gastroenterology : WJG·Enzo IerardiAlfredo Di Leo
Sep 2, 2018·The American Journal of Gastroenterology·Mei-Jyh ChenUNKNOWN Taiwan Gastrointestinal Disease Helicobacter Consortium
May 26, 2017·Journal of Pediatric Gastroenterology and Nutrition·Nicola L JonesUNKNOWN ESPGHAN, NASPGHAN
Nov 2, 2016·Gut·P MalfertheinerUNKNOWN European Helicobacter and Microbiota Study Group and Consensus panel
May 31, 2018·The Journal of Antimicrobial Chemotherapy·Jyh-Ming LiouUNKNOWN Members of the Taiwan Gastrointestinal Disease and Helicobacter Consortium
Apr 19, 2018·Arquivos De Gastroenterologia·Luiz Gonzaga Vaz CoelhoJoaquim Prado de Moraes-Filho
Oct 5, 2018·Journal of Biomedical Science·Jyh-Ming LiouUNKNOWN Taiwan Gastrointestinal Disease and Helicobacter Consortium
Apr 13, 2018·International Journal of Molecular Sciences·Bo Kyeong YoonNam-Joon Cho
May 4, 2017·Helicobacter·Javier P Gisbert, Adrian G McNicholl
Jul 26, 2018·Arquivos De Gastroenterologia·Luiz Gonzaga Vaz CoelhoJosé Vitor Zir
Jan 21, 2021·Gut and Liver·Hye-Kyung JungUNKNOWN Korean College of Helicobacter and Upper Gastrointestinal Research
Jun 8, 2021·The Korean Journal of Internal Medicine·Hye-Kyung JungUNKNOWN Korean College of Helicobacter and Upper Gastrointesinal Research
Jul 6, 2021·Indian Journal of Gastroenterology : Official Journal of the Indian Society of Gastroenterology·Shivaram Prasad SinghVikram Kate

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.